Translation of Parkinson's Disease Questionnaire -8 in Urdu Language

Sponsor
Riphah International University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05405153
Collaborator
(none)
50
1
8.5
5.9

Study Details

Study Description

Brief Summary

Cross cultural analytical study to translate Parkinson's disease questionnaire-8 in Urdu language. Along with the translated version by evaluating its validity and reliability among the patients of Parkinson's disease. No such study has been previously conducted in Pakistan which translate this questionnaire in

Urdu and follows the proper cross- culture adaptation. Condition or disease:

Parkinson's disease. Convenient sampling technique would be used

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Parkinson's Disease Questionnaire-8 (PDQ-8) is the brief version of PDQ-39 formulated to reduce the respondent burden and for convenient use in clinical settings in patients of Parkinson's disease. (PDQ-8) is the patient reported outcome measure constructed by taking one question from each of the eight domains of PDQ-39 (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. PDQ-8 will be translated into Urdu language by Beaton et al guidelines for cross cultural adaptation of tool. The validity and reliability of Urdu version of PDQ-8 will be evaluated by calculating Cronbach's alpha, intra-class correlation coefficient and Pearson/spearman rank correlation co-efficient.

    Continuous variables will be shown by mean and standard deviation and the categories will be demonstrated in frequency and percentage. Factor structure of the PDQ-8 will be extracted using exploratory factor analysis (EFA), utilizing principal component analysis with varimax rotation.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Urdu Version of Parkinson's Disease Questionnaire-8. A Cross-cultural Validity and Reliability Study
    Actual Study Start Date :
    May 5, 2022
    Anticipated Primary Completion Date :
    Jan 15, 2023
    Anticipated Study Completion Date :
    Jan 20, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Parkinson's disease questionnaire (PDQ-8) [8 months]

      Parkinson's disease Questionnaire-8 (PDQ-8) is the brief version of PDQ-39 formulated to reduce the respondent burden and for convenient use in clinical settings in patients of Parkinson's disease. (PDQ-8) is the patient reported outcome measure constructed by taking one question from each of the eight domains of PDQ- 39 (mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort)

    Secondary Outcome Measures

    1. Reliability of translated versions of PDQ-8 [8 months]

      To determine the reliability of cross-culturally adapted and translated PDQ-8 in the patients with Parkinson's disease. Reliability or reproducibility refers to the ability of a measure to produce the same results when administered at two intervals between different visits of the patient. Thus, the reliability of tool will be assessed by internal consistency and test-retest reliability

    2. Validity of translated versions of PDQ-8 [8 months]

      To determine the validity of cross-culturally adapted and translated PDQ-8 in the patients with Parkinson's disease. Validity is how accurate the results are.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    40 Years to 65 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 40-65 years

    • Both genders

    • Patients with diagnosed Idiopathic Parkinson's disease (IPD) by neurophysician

    • Patient able to read Urdu Language. Patients who can participate in community, patients with cognitive issue, Patients with MMSE more than 24 will be included

    Exclusion Criteria:
    • Patients with any other neurological issue

    • Patients who undergo brain surgery

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Lahore Lahore Punjab Pakistan 54000

    Sponsors and Collaborators

    • Riphah International University

    Investigators

    • Principal Investigator: Tehreem Mukhtar, MS, Riphah International University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Riphah International University
    ClinicalTrials.gov Identifier:
    NCT05405153
    Other Study ID Numbers:
    • RiphahIU Nayab Khurram
    First Posted:
    Jun 6, 2022
    Last Update Posted:
    Jun 6, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Riphah International University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jun 6, 2022